Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 15, 2017 (Vol. 37, No. 4)

Good Assays for Bad Immunogenicity

Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs

  • With some medical interventions, immunogenicity is the whole point—hence the “good” immunogenicity provoked by vaccines. Immunogenicity is much to be avoided, however, when biotherapeutics are deployed. Biotherapeutics such as recombinant proteins or monoclonal antibodies (mAbs) may instigate “bad” immunogenicity, potentially nullifying any hoped-for benefits or even causing autoimmune reactions. ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.